厦门艾德生物医药科技股份有限公司 证券代码：300685 证券简称：艾德生物 公告编号：2025-070 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于 2025 年 12 月 25 日召开 2025 年第二次临时股东会，审议通过了《关于修订〈公 司章程〉的议案》。 为保证公司董事会的规范运作，公司于 2025 年 12 月 25 日召开了职工代表 大会，经全体与会职工代表表决，选举阮力先生（简历详见附件）为公司第四届 董事会职工代表董事，任期自本次职工代表大会选举之日起至第四届董事会任期 届满之日止。阮力先生原为公司第四届董事会非独立董事，当选公司第四届董事 会职工代表董事后，将继续同时担任第四届董事会战略发展委员会委员职务。公 司第四届董事会构成人员不变，董事会成员数量仍为 7 名，其中兼任高级管理人 员以及由职工代表担任的董事人数总计未超过公司董事总人数的二分之一，符合 相关法律法规及《公司章程》的规定。 特此公告。 厦门艾德生物医药科技股份有限公司 董 ...

Investment Rating - The industry rating is "Overweight" and has been maintained from the previous rating [4] Core Insights - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [12] - The Chinese IVD market is expected to increase from RMB 71.3 billion in 2018 to RMB 415.2 billion by 2030, with a CAGR of 15.8%, significantly outpacing the global average [13] - The immunodiagnostics market in China is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [16] - The POCT market is also expanding quickly, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023, with a CAGR of 19.52% [20] - The molecular diagnostics market, despite a decline from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, still shows potential with a market size exceeding RMB 10 billion when excluding emergency-related factors [25] Summary by Sections IVD Market Outlook - The IVD industry began in the 1950s and has seen significant growth due to advancements in medical technology and increasing health demands [11] - The Chinese IVD market has diversified into various diagnostic technologies, including biochemical, immunological, POCT, molecular, and pathological diagnostics [15] Immunodiagnostics Market - The immunodiagnostics market is the largest segment in China's IVD market, accounting for over 40% in 2023 [15] - The market is expected to face some deceleration due to price reductions from centralized procurement policies [16] Biochemical Diagnostics Market - The biochemical diagnostics market in China grew from RMB 17.1 billion in 2021 to RMB 19 billion in 2023, with a CAGR of 5.41% [19] - Domestic products dominate this market with over 70% market share [19] POCT Market - The POCT market is driven by convenience and increased demand for home testing, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023 [20] Molecular Diagnostics Market - The molecular diagnostics market has faced challenges, declining from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, primarily due to reduced demand post-pandemic [25] Pathogen Microbiology Market - The pathogen microbiology diagnostics market in China is projected to grow from RMB 16.82 billion in 2018 to RMB 90.27 billion by 2030, with a CAGR of 15.0% [30]

证券日报网讯12月22日，艾德生物（300685）在互动平台回答投资者提问时表示，公司高度重视股东回 报与市值管理，将持续优化经营策略，提升核心竞争力。 ...

（编辑 任世碧） 证券日报网讯 12月22日，艾德生物在互动平台回答投资者提问时表示，公司实验室已应用了实验室信 息管理系统。公司始终坚持以患者为中心，紧密围绕临床实际需求，深耕肿瘤基因检测领域，聚焦于药 物伴随诊断，依托强大生信算法，布局试剂、软件及配套仪器，并提供专业的检测服务及药物临床研究 服务。 ...

格隆汇12月22日丨艾德生物(300685.SZ)在投资者互动平台表示，公司目前未开展基因芯片业务。 ...

格隆汇12月22日丨艾德生物(300685.SZ)在投资者互动平台表示，公司目前未开展基因芯片业务。 ...

Market Overview - The Shanghai Composite Index closed at 3884.93 points, with a slight decline of -0.11% [1] - The total trading volume of A-shares reached 1,198.5 billion yuan [1] Stocks with Death Cross - A total of 88 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between the 5-day and 10-day moving averages include: - Chuling Information (300250) with a distance of -1.55% [1] - Rongji Software (002474) with a distance of -1.40% [1] - Changyuan Donggu (603950) with a distance of -1.25% [1] Individual Stock Performance - Chuling Information (300250) saw a decline of -6.37% with a trading turnover rate of 11.94% [1] - Rongji Software (002474) decreased by -1.83% with a turnover rate of 10.53% [1] - Changyuan Donggu (603950) fell by -1.09% with a turnover rate of 0.41% [1] - Other notable declines include: - Shenhua A (000020) down -2.80% [1] - Sunshine Power (300274) down -3.41% [1] - Aide Biological (300685) down -3.43% [1] Additional Stock Data - Stocks with minor declines include: - Yitian Intelligent (300911) down -0.86% [2] - Hanrui (300618) down -1.70% [2] - Yinghe Technology (300457) down -3.03% [2] - Stocks with slight increases include: - Jinfatech (600143) up 0.67% [2] - Degoo (300950) up 0.13% [2]

（文章来源：证券日报） 证券日报网讯 12月12日晚间，艾德生物发布公告称，公司于近日收到欧洲专利局颁发的发明专利证 书，专利名称为一种用于核酸富集捕获的探针及设计方法。 ...

每经AI快讯，艾德生物（SZ 300685，收盘价：21.55元）12月12日晚间发布公告称，公司于近日收到欧 洲专利局颁发的发明专利证书。专利名称为"一种用于核酸富集捕获的探针及设计方法"。 2024年1至12月份，艾德生物的营业收入构成为：体外诊断行业占比100.0%。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 （记者 贾运可） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，艾德生物市值为84亿元。 ...

艾德生物12月12日公告，公司于近日收到欧洲专利局颁发的发明专利证书。发明专利名称：一种用于核 酸富集捕获的探针及设计方法，专利号：EP3480310，专利类型：发明专利，专利申请日：2017年6月 28日，专利权期限：自申请日起二十年。上述发明专利为公司自主研发，已在公司相关产品上应用。 ...